← Sapienti
SAPIENTI · Implications Brief SB-2026-014 · 27 Jun 2026 Illustrative sample · public data

FDA user-fee reauthorization: what it means for a mid-cap specialty manufacturer

PDUFA reauthorization has reopened the fee structures that touch every product in your pipeline. Here is where you are exposed, how it likely resolves, and what to do now — with our confidence and our blind spots shown.

As of 27 Jun 2026 Overall confidence · medium-high
Bottom line

A clean reauthorization remains the most likely outcome (≈58%), but the adverse path — higher application and program fees phased in from FY27 — is now material enough to hedge. Lock filing timing and budget assumptions this quarter; the cost of acting is far below the cost of waiting.

The situation

What's happening

The FDA's prescription-drug user-fee program is up for reauthorization before the 30 September deadline. Committee negotiations have reopened fee tiers and performance goals, and both industry and the agency have signalled openness to restructuring application and program fees. A failure to reauthorize would trigger a short stopgap and a review pause.

Exposure

Where it touches you

FY27 revenue at risk14%▼ pipeline-weighted
Filings in the window3NDAs, Q3–Q4
Modeled fee delta$2.1–3.4M▼ per year, adverse case

Modeled annual program-fee burden, FY26 → FY29. Solid = observed · amber = now · dashed = central case · cone = confidence band (widens as the markup schedule firms up).

Impact × scenarios

How it resolves — and what each path costs you

Clean reauthorization

Fees rise with inflation only; review timelines hold. The herd's base case — and ours.

Most likely ≈58%

Reform with new fee tiers

Application + program fees up 18–26%; +$2.1–3.4M/yr; filing economics shift toward fewer, larger submissions.

Material ≈31%

Lapse → short stopgap

30–60 day review pause; a Q4 filing slips into FY27, moving a launch and its revenue.

Tail risk ≈11%
Recommended actions

What to do now

  1. Pull the two Q4 NDA filings forward into Q3.

    Hedges the lapse path entirely and de-risks the launch calendar. Low regret even in the base case.

    This quarterHigh

  2. Budget FY27 fees at the adverse case, not the base case.

    Carry the +26% assumption into planning now; release the reserve if a clean reauthorization lands. Protects the P&L against the path you can't control.

    Before FY27 plan lockHigh

  3. Engage your trade association on the tier language — now.

    The program-fee tiering is the one lever where you can still move the outcome, and the window closes at markup.

    Before markupMedium

  4. Re-run this brief when the markup date confirms.

    That single unknown (below) is what most sharpens the adverse probability — we'll refresh the moment it lands.

    On trigger
What we don't know

The blind spots in this brief

Data gap no CBO score on the fee restructuring yet — the adverse magnitude is a modeled estimate Data gap committee markup date unconfirmed — timing of resolution is uncertain Data gap FDA fee tables not published past 2026-06 — FY27 baseline is extrapolated

These gaps widen the bands above — they do not change the recommended actions, which are low-regret across every scenario.